Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Colorcon
US Department of Justice
McKesson
Daiichi Sankyo
McKinsey
Julphar
US Army
Cipla

Generated: June 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,072,836

« Back to Dashboard

Which drugs does patent 9,072,836 protect, and when does it expire?

Patent 9,072,836 protects ADLYXIN and is included in one NDA.

This patent has twenty patent family members in fifteen countries.
Summary for Patent: 9,072,836
Title:Drive mechanism for a drug delivery device and drug delivery device
Abstract: A lead screw, a lead screw nut and a drive member are aligned with an axis defining an axial direction and an opposite axial direction. A coupling between the lead screw and the lead screw nut allows a helical movement of the lead screw with respect to the lead screw nut at least in the axial direction. The lead screw is coupled with the drive member, the coupling generating a helical movement of the lead screw with respect to the drive member when the drive member is moved in the axial direction with respect to the lead screw. A dispense stop feature of the lead screw nut and a dispense stop feature of the drive member prevent the generation of the helical movement of the lead screw when a specified end position of the drive member is approached.
Inventor(s): Plumptre; David Aubrey (Worcestershire, GB)
Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH (Frankfurt am Main, DE)
Application Number:13/825,841
Patent Claim Types:
see list of patent claims
Use; Delivery; Device;

Drugs Protected by US Patent 9,072,836

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sanofi-aventis Us ADLYXIN lixisenatide SOLUTION;SUBCUTANEOUS 208471-001 Jul 27, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Sanofi-aventis Us ADLYXIN lixisenatide SOLUTION;SUBCUTANEOUS 208471-002 Jul 27, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,072,836

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
10186736Oct 6, 2010
PCT Information
PCT FiledOctober 05, 2011PCT Application Number:PCT/EP2011/067418
PCT Publication Date:April 12, 2012PCT Publication Number: WO2012/045794

International Family Members for US Patent 9,072,836

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011311617 ➤ Try a Free Trial
Brazil 112013006949 ➤ Try a Free Trial
Canada 2811953 ➤ Try a Free Trial
China 103228310 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Cipla
Medtronic
McKesson
Moodys
Harvard Business School
Baxter
Healthtrust
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.